In the current study, FGFR1 and MET amplifications were restricted to the EGFRwt/KRASwt tumor group, and were mutually exclusive (MET amplification was borderline non-significant for difference in frequency between mutation groups, p=0.09, Fisher’s exact test). The gene discussed is FGFR1; the disease is neoplasm.